Found 18 clinical trials
Postoperative Adjuvant Treatment of Completely Resected Mucosal Melanoma Phase II Study
A mucosal melanoma postoperative adjuvant treatment of multicenter, randomized, double-blind, placebo-controlled phase II study, evaluation of mucosal melanoma patients accept completely resected, Toripalima Combined with Temozolomide and Cisplatin postoperative adjuvant therapy efficacy and safety
- 0 views
- 19 Feb, 2024
Maintenance Treatment of Toripalimab(JS001) in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma
This study is a multicenter, single-arm, open, phase clinical study to evaluate the safety and efficacy of Toripalimab(JS001) monoclonal injection after chemotherapy in combination with Endostar for Locally Advanced or Metastatic Mucosal Melanoma.
- 0 views
- 19 Feb, 2024
PHP and Immunotherapy in Metastasized UM
Melanoma of the eye (ocular/uveal melanoma) is an uncommon type of cancer that is associated with a high mortality. It usually disseminates rapidly throughout the body, most commonly to the liver and lungs.
- 0 views
- 19 Feb, 2024
The Study of IBI310 in Combination With IBI308 Compared to High-Dose Interferon In Patients With Acral Melanoma That Has Been Removed by Surgery
This is a phase III randomized, control, multi-center study of recombinant humanized anti-PD-1 mAb in combination with CTLA4 mAb for injection compared to high-Dose interferon in patients with acral melanoma that has been removed by surgery.
- 0 views
- 19 Feb, 2024
Intratumoral Tilsotolimod a TLR-9 Agonist Together With Intratumoral Ipilimumab and Intravenous Nivolumab in Patients With Advanced Cancers
The trial will be divided into two parts: PART A: the first part will assess the safety of two regimen and will recruit patients with all types of injectable solid malignancies PART B: the second part will include 3 expansion cohorts of 15 patients: B1: anti-PD-1 refractory advanced NSCLC cohort …
- 0 views
- 19 Feb, 2024
4SCAR-CD44v6 T Cell Therapy Targeting Cancer
The purpose of this clinical trial is to assess the feasibility, safety and efficacy of 4SCAR-CD44v6 T-cell therapy targeting multiple cancers. The study also aims to learn more about the function of the CD44v6 CAR-T cells and their persistency in the patients.
- 0 views
- 19 Feb, 2024
JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations
This is a Phase 1 study of JSI-1187 as monotherapy and in combination with dabrafenib for the treatment of advanced solid tumors with MAPK pathway mutations, including mutations that cause MAPK pathway hyperactivation.
- 0 views
- 19 Feb, 2024
Neoadjuvant T-VEC in High Risk Early Melanoma
The investigators propose an open-label, Phase 2 study of talimogene laherparepvec (T-VEC), in the neoadjuvant setting for patients with high-risk, resectable primary and cutaneous melanoma prior to definitive excision. The central hypothesis of this proposal is that neoadjuvant intra-lesional therapy with T-VEC in high risk early stage melanoma will effectively …
- 0 views
- 19 Feb, 2024
Dose Escalation of DF6002 in Patients With Advanced Solid Tumors and Expansion in Selected Indications
This study is a Phase 1/2, open-label, dose-escalation study with a consecutive parallel-group efficacy expansion study, designed to determine the safety, tolerability, PK, pharmacodynamics, and preliminary anti-tumor activity of DF6002 as monotherapy and in combination with pembrolizumab.
- 0 views
- 19 Feb, 2024
A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab
The purpose of this phase I/Ib study is to determine the safety profile of NIZ985 (new formulation), and if it can be safely combined with Spartalizumab and to determine the appropriate dose and schedule for further study. Moreover, the study will characterize the pharmacokinetic profiles of NIZ985 as a single …
- 0 views
- 19 Feb, 2024
- 1
- 2